Cost analysis of patiromer vs sodium zirconium cyclosilicate for the treatment of hyperkalemia in Spain and the UK.

Antonio Ramirez de ArellanoGabrielius Jakutis Barnaby Hunt

Published in: Journal of medical economics (2024)

Patiromer has the potential to be cost saving vs SZC for the treatment of hyperkalemia in Spain and the UK based on the results of a real-world evidence analysis.

Keyphrases

cross sectional
combination therapy
risk assessment
replacement therapy